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Abstract
Introduction Age is one of the most important risk factors for
human malignancies, including breast cancer; in addition, age at
diagnosis has been shown to be an independent indicator of
breast cancer prognosis. Except for inherited forms of breast
cancer, however, there is little genetic or epigenetic
understanding of the biological basis linking aging with sporadic
breast cancer incidence and its clinical behavior.
Methods DNA and RNA samples from matched estrogen
receptor (ER)-positive sporadic breast cancers diagnosed in
either younger (age ≤ 45 years) or older (age ≥ 70 years)
Caucasian women were analyzed by array comparative genomic
hybridization and by expression microarrays. Array comparative
genomic hybridization data were analyzed using hierarchical
clustering and supervised age cohort comparisons. Expression
microarray data were analyzed using hierarchical clustering and
gene set enrichment analysis; differential gene expression was
also determined by conditional permutation, and an age
signature was derived using prediction analysis of microarrays.
Results Hierarchical clustering of genome-wide copy-number
changes in 71 ER-positive DNA samples (27 younger women,
44 older women) demonstrated two age-independent
genotypes; one with few genomic changes other than 1q gain/
16q loss, and another with amplifications and low-level gains/
losses. Age cohort comparisons showed no significant
differences in total or site-specific genomic breaks and amplicon
frequencies. Hierarchical clustering of 5.1 K genes variably
expressed in 101 ER-positive RNA samples (53 younger
women, 48 older women) identified six transcriptome subtypes
with an apparent age bias (P  < 0.05). Samples with higher
expression of a poor outcome-associated proliferation signature
were predominantly (65%) younger cases. Supervised analysis
identified cancer-associated genes differentially expressed
between the cohorts; with younger cases expressing more cell
cycle genes and more than threefold higher levels of the growth
factor amphiregulin (AREG), and with older cases expressing
higher levels of four different homeobox (HOX) genes in addition
to ER (ESR1). An age signature validated against two other
independent breast cancer datasets proved to have >80%
accuracy in discerning younger from older ER-positive breast
cancer cases with characteristic differences in AREG  and
ESR1 expression.
Conclusion These findings suggest that epigenetic
transcriptome changes, more than genotypic variation, account
for age-associated differences in sporadic breast cancer
incidence and prognosis.
Introduction
Age is the strongest demographic risk factor for most human
malignancies, including breast cancer [1]. About 80% of all
breast cancers occur in women older than age 50; the 10-year
probability of developing invasive breast cancer increases
from <1.5% at age 40, to about 3% at age 50 and to >4% by
CGH = comparative genomic hybridization; ER = estrogen receptor; GO = gene ontology; GSEA = gene set enrichment analysis; MAPK = mitogen-
activated protein kinase; NCI-Bari = National Cancer Institute – Bari; PAM = prediction analysis of microarrays; PR = progesterone receptor; UCSF 
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age 70, resulting in a cumulative lifetime risk of 13.2% (one in
eight) and a near ninefold higher incidence rate in women
older than age 50 as compared with their younger counter-
parts [2,3]. Despite awareness that breast cancer and other
cancers are primarily age-related diseases, molecular and cel-
lular hypotheses explaining the cancer–aging relationship
have only recently emerged and remain clinically unproven [4].
At the subcellular level, normal human aging has been linked
to increased genomic instability [5,6], to global and promoter-
specific epigenetic changes [7,8], and to altered expression of
genes involved in cell division and extracellular matrix remode-
ling [5,6]. These associations have led to the hypothesis that
the cancer-prone phenotype of an older individual results from
the combined effects of cumulative mutational load, increased
epigenetic gene silencing, telomere dysfunction and altered
stromal milieu [9]. Given the worrisome social, economic and
medical consequences of an aging worldwide population, pro-
posed biological mechanisms linking cancer with aging must
be established in order to develop effective interventions.
As with normal organs and tissues, tumor biology can also
change with aging [10,11]. For sporadic breast cancer in par-
ticular, correlations between patient age at diagnosis, tumor
biology and clinical prognosis have long been appreciated if
not fully understood [12-16]. Younger age at diagnosis (≤ 45
years old) is associated with more aggressive breast cancer
biomarkers, including overexpression of ERBB2/HER2 and
ERBB1/HER1 growth factor receptors [13], abnormal p53
expression [13,15], estrogen receptor (ER) negativity [12-16],
higher nuclear grade and higher Ki-67 proliferation index [12-
14,16]. These breast cancer biomarkers are also interdepend-
ent, however; in particular, ER expression is inversely corre-
lated with abnormal p53 [15], overexpression of ERBB2 [15],
high Ki-67 and nuclear grade, and poor patient prognosis [17].
It therefore remains unclear whether the age-specific biomar-
ker features of breast cancer reflect the pleotropic back-
ground effects of aging on the normal mammary gland or age-
specific differences in breast tumorigenesis; also, since most
age-specific biomarkers strongly associate with the ER status,
the effects of aging must be studied in histologically similar
breast cancer phenotypes controlled for ER status.
The molecular and cellular effects of aging on both normal and
malignant breast tissue are superimposed on a continuum of
developmental changes that normally occur between puberty
and menopause, heavily influenced by menstrual history and
parity. In general, the normal mammary gland ER content (fmol
receptor/g tissue) as well as the proportion of ER-expressing
(ER-positive) ductal epithelial cells increase with each decade
of age, and reach a plateau with menopause at about age 50
[18,19]. In contrast, breast cancer ER expression continues to
rise beyond menopause, reaching a near 25-fold differential
between normal and malignant mammary gland ER expression
in patients by age 70 [18].
Curiously, expression of some ER-inducible gene markers,
such as progesterone receptor (PR), pS2, Bcl2 and cathepsin
D, does not show any significant relationship with the age at
diagnosis [13,18], while other markers show increased
expression in breast cancers arising earlier in life [20] – sug-
gesting that the effects of aging may in part be attributed to
age-related differences in estrogen-inducible ER pathways.
Important in this regard is the age-related change in PR coex-
pression within ER-positive breast cancers, since PR has long
been used as a clinical indicator for a functioning ER pathway
in tumors likely to respond to endocrine therapy [21]. Among
all ethnic patient groups, ER-positive/PR-negative breast can-
cers show the greatest age-related increase in incidence after
age 40 [22]. Potentially relevant to this ER-positive/PR-nega-
tive phenotype is the fact that growth-factor-activated path-
ways downregulate PR expression [22-25], and that the
inverse correlation between overexpression of the ERBB2
growth factor receptor and PR positivity is only seen in breast
cancers arising after age 40 [26]. Surprisingly, the natural per-
imenopausal decline in ovarian-produced estrogen serum lev-
els do not fully account for age-related changes in ER-
regulated mammary epithelial pathways, since the marked
age-related increase in stromal and epithelial aromatase
expression produces postmenopausal mammary gland estro-
gen levels comparable with those measured in premenopausal
women [27].
To better understand the molecular and cellular influences of
aging on breast cancer biology and clinical behavior, we per-
formed a detailed study of phenotypically similar breast can-
cers arising in two disparate patient age groups. The DNA and
the RNA were prospectively extracted from cryobanked sam-
ples of stage-matched and histology-matched ER-positive
breast cancers diagnosed in either younger (age ≤ 45 years)
or older (age ≥ 70 years) Caucasian women. These samples
were analyzed by array comparative genomic hybridization
(CGH) and by high-throughput expression microarrays to look
for genetic and epigenetic differences between the age
cohorts. Unsupervised hierarchical clustering of the combined
data from both cohorts was used to search for age biases in
clustered subsets, and this was followed by supervised com-
parisons between the two cohorts to delineate potential age-
related genomic and transcriptome differences. Finally, a pre-
dictive analysis of microarrays (PAM) performed on the two
age cohorts produced an age-specific expression signature
that proved to have >80% predictive accuracy when validated
against two other independent breast cancer datasets.
Materials and methods
Breast cancer samples extracted for DNA and RNA
Cryobanked breast cancer specimens excised from newly
diagnosed Caucasian females were obtained from the Univer-
sity of California San Francisco (UCSF) Comprehensive Can-
cer Center Breast Oncology Program Tissue Core (n = 66)
and from the National Cancer Institute – Bari (NCI-Bari) (n =Available online http://breast-cancer-research.com/content/9/5/R59
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71), following multi-institutional review board approvals.
Tumor specimen selection criteria included sporadic inci-
dence (no first-degree relatives with breast cancer), >50%
invasive cancer cellularity, a frozen wet weight of at least 100
mg, ER-positivity (>10% nuclear immunohistochemical stain),
and patient age at diagnosis either ≤ 45 years (younger cases)
or ≥ 70 years (older cases). The 66 UCSF cases were all
node-negative and were of predominantly ductal histology
(60/66); 54 cases were associated with outcome annotation.
The 71 NCI-Bari cases were all of ductal histology with mixed
nodal status and without any outcome annotation. The two age
cohorts within both tumor sets showed no significant imbal-
ances in the stage, the grade, and the PR status or ERBB2
status. PR-positivity was defined as ≥ 10% nuclear immuno-
histochemical staining, and ERBB2-positivity was defined as
gene amplification.
Cryobanked specimens were pulverized under liquid nitrogen
prior to nucleic acid extraction. DNA was purified from frozen
tumor powders using the High Pure PCR Preparation Kit
(Roche Diagnostics, Indianapolis, IN, USA) and its quality was
verified by gel electrophoresis. Total RNA was purified using
Trizol reagent as per the manufacturer's protocol (Invitrogen,
Carlsbad, CA, USA). Some RNA samples initially stored in for-
mamide were further purified through RNeasy columns
according to the manufacturer's protocol (QIAGEN, Valencia,
CA, USA). All RNA samples were quality verified on a bioana-
lyzer (Agilent Technologies, Palo Alto, CA, USA). DNA from all
71 NCI-Bari specimens were used for array-based CGH anal-
ysis, but only 35 of these specimens also yielded sufficient
RNA for expression microarray analysis. The 35 NCI-Bari RNA
samples (RNA sample set 1) were therefore combined with 66
RNA samples prepared from the UCSF specimens (RNA sam-
ple set 2) to yield 101 total RNA samples (53 younger women,
48 older women) for expression microarray analysis.
Array comparative genomic hybridization and data 
processing
Array CGH and data processing were carried out as
described in reference [28]. Test and reference genomic
DNAs (500–1,000 ng) were labeled with Cy3 and Cy5,
respectively, in a random priming reaction using 25–50 μl
reaction volumes. The two labeled DNAs together with Cot-1
DNA (100 μg) were hybridized for 48–72 hours at 37°C onto
arrays of 2,464 BAC clones, each printed in triplicate
(HumArray1.14 and Hum-Array2.0; UCSF Comprehensive
Cancer Center Microarray Core). Data from both array ver-
sions were combined only for the BAC clones present on both
arrays; duplicate clones were averaged and the final dataset
contained 2,240 unique BACs. Images were acquired and the
data were processed as previously described [28]. For each
tumor, data were plotted in genome order as the mean log2
ratio of the replicate spots for each clone normalized to the
genome median log2 ratio. Array CGH data were deposited in
the public Gene Expression Omnibus database (GSE8801).
Array CGH data were analyzed using circular binary segmen-
tation [29] with default parameters to translate intensity meas-
urements into regions of equal copy number, as implemented
in the DNAcopy R/Bioconductor package [30]. Missing values
were imputed using the maximum value of two flanking seg-
ments, producing smoothed values. The gain and loss status
for each probe was assigned using the mergeLevel procedure
[31]. Tumor profiles were clustered using smoothed imputed
data with outliers present; and agglomerative hierarchical clus-
tering was performed using the Euclidean distance as a simi-
larity measure and using the Ward method to minimize the sum
of variances to produce compact spherical clusters. A clone-
wise comparison of the phenotypic groups was made by t-
testing smoothed values and controlling for the false discovery
rate, with a false-discovery-rate-adjusted P value ≤ 0.05 for
significance. The Kruskal–Wallis rank sum test was used to
analyze phenotypic associations with the following autosomal
genomic parameters: the number of break points and chromo-
somes with break points, the number of amplifications and
chromosomes with amplifications, the number of whole chro-
mosome changes and the fraction of genomes altered.
The fractions of genome gained and lost were computed for
each tumor, and the frequency of alterations at each clone was
computed as the proportion of samples showing an alteration
at that locus. The amplification status for a clone was deter-
mined by considering the width of the segment to which that
clone belonged (0, if an outlier) and a minimum difference
between the smoothed value of the clone and the segment
means of the neighboring segments. A clone was declared
amplified if it belonged to the segment spanning less than 20
Mb and the minimum difference was greater than exp(-x3),
where x is the final smoothed value for the clone. This proce-
dure allowed clones with small log2-ratio values to be declared
amplified if they were high relative to surrounding clones. To
calculate the number of chromosomes with amplifications, a
chromosome was said to be amplified if at least one of its
clones was amplified. Whole chromosome changes were
assigned to chromosomes without identified breakpoints if a
chromosomal segment mapped to a gain or a loss level. The
number of chromosomal break points was calculated as the
number of copy number levels within each chromosome
across the genome minus the number of chromosomes. To
calculate the number of chromosomes with break points, at
least one break point per chromosome was necessary.
Microarray expression profiles and data processing
The total RNA (3–5 μg per sample) was labeled and analyzed
using Affymetrix (Santa Clara, CA, USA) HT-HG_U133A Early
Access Arrays with 22.9 K probes representing ~13 K unique
UniGenes. Analyses were performed by standard Affymetrix
procedures within the Lawrence Berkeley National Laboratory
and Life Science Divison's Molecular Profiling Laboratory [32].
Probe set measurements were generated from quantified
Affymetrix image files (.CEL files) using the RMA algorithm inBreast Cancer Research    Vol 9 No 5    Yau et al.
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Bioconductor R. Array data were deposited in the public Gene
Expression Omnibus database (GSE7378 and GSE8193).
Gene expression values were mean centered, with a low vari-
ation filter applied to exclude probe sets that did not have at
least 10 observations exhibiting a twofold change from the
mean. Filtered probes were annotated (GeneTraffic annotation
file, March 2006) and those with unknown UniGene symbols
were omitted, yielding a final significant probe set of 6,632
annotated probes representing 5,109 unique genes. Unsuper-
vised hierarchical clustering of the mean centered significant
probe set was performed using Cluster [33], and was visual-
ized with Java TreeView [34]. Phenotypes (for example, age
cohort, PR status and ERBB2 status) of the resulting clusters
were compared by chi-square test.
Gene set enrichment analysis (GSEA) was performed using
GSEA software (version 2.01) [35,36] to assess tumor pheno-
types (for example, age cohort, PR status or ERBB2 status)
with respect to specific gene signatures including a mitogen-
activated protein kinase (MAPK)-regulated gene set [37], a
luminal tumor subtype gene set [38] and a proliferation-asso-
ciated gene set [39]. The enrichment of all curated gene sets
(c2) within the Molecular Signature Database [36], satisfying
the gene set size-filtering criteria (maximum = 500, minimum =
10), were also evaluated. Ranking of UniGenes within each
phenotype was based on a signal-to-noise metric; an enrich-
ment score for each signature was derived as a function of the
likelihood of that gene set being among the most highly ranked
genes within the phenotype. For genes represented by more
than one probe, the median expression level of all correspond-
ing gene probes was used; the significance of the enrichment
score was estimated by 1,000 random permutations of the
sample labels in the tumor dataset. For gene sets showing sta-
tistically significant enrichment with respect to the age cohort
(P < 0.05), unsupervised clustering was performed on the
entire set of RNA samples using those genes; the outcome
association of high gene set expressors versus low gene set
expressors was also tested by Kaplan–Meier analysis of the
54 cases with known recurrence events.
A conditional permutation test was performed to identify differ-
entially expressed genes with respect to age and conditional
on the RNA sample sources (NCI-Bari and UCSF). For each
gene, a linear-fit model of expression level versus age cohort
was adjusted for the categorical sample source, and the P
value was based on the t statistic on the slope of age. The null
distribution used, however, was not the standard normal but
was based on permuting the age cohort distribution within
each sample source, which provides an exact test of the con-
ditional independence of age given the sample source. This
was expected to control for possible different age effects
within each sample source, and to adjust for potential spurious
associations based on the different sample sources [40].
Reported associations between the differentially expressed
genes and either cancer or aging were determined using the
MEDGENE database [41,42], entering the following search
terms: Neoplasm, Breast Neoplasms, Carcinomas, Breast
Carcinomas, and Aging, Premature. Functional annotation of
the differentially expressed genes was performed by gene
ontology (GO) analysis [43]; significant enrichment for spe-
cific biological functional categories (≥ 5 probes within a proc-
ess class, Expression Analysis Systematic Explorer [44] score
<0.05) was identified from the DAVID database [43,45].
An age cohort gene signature was obtained by training PAM
software [46] on RNA sample set 2 (UCSF), minimizing the
cross-validation error for the individual age cohorts. The result-
ing PAM classifier was used to predict the age cohort of RNA
sample set 1 (NCI-Bari). For external validation purposes,
expression microarray data from Miller and colleagues [47]
and from Sotiriou and colleagues [48] were downloaded from
the NCBI public Gene Expression Omnibus database
(GSE3494 and GSE2990). ER-positive cases with age char-
acteristics matching our age cohorts were selected, resulting
in 102 cases from Miller and colleagues' study and 47 cases
from Sotiriou and colleagues' study. As the training set (RNA
sample set 2) comprised only early-stage tumors, PAM valida-
tion was also performed on the external datasets restricted to
only ER-positive, node-negative cases (35 cases from Sotiriou
and colleagues [48], and 64 cases from Miller and colleagues
[47]). Since these microarray studies used Affymetrix U133A
platforms, probe set measurements were generated using the
RMA algorithm in Bioconductor R and the resulting data were
mapped to our significant gene set by Affymetrix probe identi-
fiers, to which the PAM classifier was applied. The significance
of the prediction accuracy was determined using Fisher's
exact test.
Results
Age and ER-positive breast cancer genomic profiles
Array CGH at 1 MB resolution was performed on 71 ER-pos-
itive primary breast cancer DNA samples from the two age
cohorts: 27 younger cases and 44 older cases, matched for
stage and histology (nodal status, grade, PR status). Unsuper-
vised hierarchical clustering of the genome-wide copy number
changes (smoothed log2  ratios), as shown in Figure 1,
revealed that these ER-positive cancers comprise two basic
genome aberration patterns that have been previously charac-
terized from unselected breast cancer collections [28]: a sim-
ple genotype with few genomic copy number changes other
than gain of 1q and loss of 16q, and a mixed amplifier geno-
type with recurrent amplifications and low-level genomic gains
and losses. Neither the two primary dendrogram clusters rep-
resenting these two basic genotypes nor any of the secondary
dendrogram clusters exhibit any bias (P > 0.3, Fisher exact
test) with respect to age, nodal status or PR status. Direct
comparison of the two age cohorts for multiple array CGH
parameters revealed no significant differences in the number
of break points, chromosomes with break points,Available online http://breast-cancer-research.com/content/9/5/R59
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amplifications, chromosomes with amplifications, or whole
chromosome changes; also, the fraction of genome gained,
lost or otherwise altered were not significantly different
between the two age cohorts (Additional file 1). While nonsig-
nificant trends suggested slightly fewer oncogene amplifica-
tions within the older cohort, overall amplification frequencies
for the most common oncogene loci were as follows: MYC
(8q24.2; 27%), CCND1 (11q13.3; 23%), ZNF217 (20q32;
17%), AIB1 (20q13.12; 16%), MDM2 (12q15; 8%), ESR1
(6q25; 7%), ERBB2 (17q12; 7%), and TOPO2A (17q21;
7%).
Unsupervised analysis of ER-positive breast cancer 
expression profiles
RNA sample set 1 (35 NCI-Bari RNA samples) and RNA sam-
ple set 2 (66 age-matched UCSF samples) were combined to
yield 101 RNA samples from ER-positive breast cancers, aris-
ing in the predefined younger (n = 53) and older (n = 48) age
groups, well balanced for tumor size, nodal involvement,
grade, PR status and ERBB2 status. Figure 2 shows the unsu-
pervised hierarchical clustering of these 101 breast cancer
cases, based on their gene expression similarity across nearly
5.1 K variably expressed unique genes (6,632 probe sets),
into six different transcriptome clusters of ER-positive breast
cancer (groups 1A, 1B, 2A, 2B, 3A and 3B). The four different
ESR1 probes on the array defined two primary ESR1-associ-
ated probe set clusters, including genes (for example, GATA3,
KRT8, KRT18) commonly used to define luminal-type breast
cancers [38,39,49-51]. There was an average 65-fold range in
the ESR1 transcript levels across this entire collection of 101
breast cancers, with the ESR1-associated probes showing
similar variations. The six different transcriptome clusters
showed no significant bias with respect to tumor PR status
and ERBB2 status; in contrast, two of the clusters were
Figure 1
Hierarchical clustering of primary estrogen receptor-positive breast cancers based on genome-wide DNA copy number aberrations Hierarchical clustering of primary estrogen receptor-positive breast cancers based on genome-wide DNA copy number aberrations. Unsupervised 
hierarchical clustering of 71 primary estrogen receptor-positive breast cancers, diagnosed in younger women (age ≤ 45 years) or older women (age 
≥ 70 years), based on genome-wide DNA copy number aberrations. As previously reported for BAC-based array comparative genomic hybridization 
analyses of human breast cancer samples [5], columns represent individual tumor samples and rows represent individual genome probes (BAC 
clones), ordered by chromosome and genome position with 1pter at the top and 22qter at the bottom. Chromosome p-arms and q-arms are shown 
as different shades of the same color (blue = odd numbered chromosomes, yellow = even numbered chromosomes). As indicated in the color scale 
at the bottom, genome copy number losses are indicated in red (-0.5) and copy number gains are indicated in green (0.5). Yellow dots represent 
high-level genomic amplifications. Colored and grey-toned upper bars identify the age cohort, progesterone receptor (PR) status, nodal status and 
grade status of the estrogen receptor-positive samples in each column. The dendrogram shows unsupervised classification of the 71 samples into 
two primary clusters and four secondary clusters, with no significant cluster bias according to age, PR status, nodal status or grade status (P > 0.3, 
Fisher exact test).Breast Cancer Research    Vol 9 No 5    Yau et al.
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composed primarily of younger cases (64% of group 1A, 81%
of group 2B) and one was composed primarily of older cases
(68% of group 2A).
When the cluster compositions with respect to age, PR status
and ERBB2 status were statistically compared, only the age
cohort distribution was found to be significantly different (P <
0.05, chi-square test). Patient outcome data were available on
54 (30 younger, 24 older) of the 101 cases, scattered evenly
among the six transcriptome clusters. Kaplan–Meier probabil-
ity curves for recurrence-free survival indicated that younger
age and PR-negative status were associated with earlier
relapse, but these outcome differences did not quite reach
statistical significance (age, P = 0.09; PR status, P = 0.08;
log-rank analyses). Kaplan–Meier curves for cases represent-
ing each of the six transcriptome clusters, however, did
achieve significant separation (P = 0.025, log-rank analysis),
with the predominantly younger group 2B cases showing the
shortest survival (median recurrence-free survival = 2.5 years)
and the predominantly older group 2A cases showing signifi-
cantly more prolonged survival (median recurrence-free sur-
vival = 6.2 years).
Gene set enrichment analysis
Probe sets for the variably expressed genes were subjected to
GSEA with respect to each age cohort for MAPK-regulated
Figure 2
Hierarchical clustering of primary estrogen receptor-positive breast cancers based on genome-wide microarray profiling Hierarchical clustering of primary estrogen receptor-positive breast cancers based on genome-wide microarray profiling. Unsupervised hierarchical 
clustering of 101 primary estrogen receptor (ER)-positive breast cancers, diagnosed in younger women (age ≤ 45 years) or older women (age ≥ 70 
years), based on genome-wide microarray profiling of 6,632 variably expressed probes (~5.1 K unique genes). The cluster dendrogram defines six 
different transcriptome subtypes of ER-positive breast cancers (Group 1A, 1B, 2A, 2B, 3A, 3B), with significant age biases (P < 0.05) but not 
biased by progesterone receptor (PR) status or ERBB2 status; horizontal colored bars identify the age cohort, PR status and ERBB2 status of the 
ER-positive samples in each column. The vertical red–green color scale shows log2 ratios from mean centered gene expression levels. Magnified 
views show ESR1-containing (ER-associated) probe sets within the entire cluster diagram.Available online http://breast-cancer-research.com/content/9/5/R59
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genes [37], luminal subtype markers [38] and a gene prolifer-
ation signature [39] (gene signatures in Additional file 2). As
shown in Table 1, in addition to comparing the age cohorts,
these gene signatures were used to compare PR-negative
cases versus PR-positive cases and to compare ERBB2-neg-
ative cases versus ERBB2-positive cases. There was no
enrichment of any of the three gene signatures according to
the tumor PR status; and only the proliferation signature
showed any significant relationship to the ERBB2 status, with
these proliferation genes more highly expressed in the
ERBB2-positive breast cancer cases (nominal P  = 0.01;
adjusted for multiple comparisons P = 0.02). Neither MAPK-
upregulated nor MAPK-downregulated genes showed any sig-
nificant relationship with age cohort, PR status or ERBB2 sta-
tus when multiple gene set testing was taken into account.
Luminal markers, commonly used as an expression array sig-
nature for ER-positive breast cancers, showed no significant
relationship with age cohort, ERBB2 status or PR status,
although there was a nonsignificant trend for luminal gene
expression to associate with PR-positive cases. Proliferation
genes were significantly more highly expressed in the younger
cohort (nominal P = 0.006; adjusted for multiple comparisons
P = 0.011). Interestingly, of the other 1,176 c2:curated gene
sets (passing through the size filter) similarly evaluated, none
showed significant enrichment according to age, tumor PR
status or ERBB2 status when multiple testing was accounted
for, although two notable trends were observed: cell cycle
genes, as annotated by GO (c2:500), were enriched in the
younger age cohort (nominal P = 0.006, family-wise error rate
P  = 0.118); and early response genes downregulated by
enforced expression of a naturally transforming chimeric HOX
developmental gene, NUP98-HOXA9 (c2:934) [52], were
enriched in the older age cohort (nominal P = 0.000, family-
wise error rate P = 0.112).
As shown in Figure 3a, when the proliferation genes were
used to perform unsupervised hierarchical clustering of the
101 cases, two comparably sized subsets were identified. The
subset with more highly expressed proliferation genes con-
tained most of the younger age cases (34/52) and all but one
of the ERBB2-positive cases (P  < 0.05, chi-square test).
These proliferation genes were also used to dichotomize the
54 cases with known clinical outcome; as shown in the Kap-
lan–Meier curves in Figure 3b, cases with more highly
expressed proliferation genes exhibited significantly worse
recurrence-free survival (P = 0.002, log-rank analysis).
Differential gene expression between age cohorts
A conditional permutation strategy was used to identify 75
unique genes (84 probe sets) differentially expressed
between younger and older cohorts (false discovery rate
P < 0.05), presented in Table 2. Of these genes, 24 genes
(28 probes) showed increased expression in the younger
cohort relative to the older cohort (including GREB1  and
AREG), while 51 genes (56 probes) showed increased
expression in the older cohort relative to the younger cohort
(including  ESR1). Interestingly, the estrogen-responsive
genes, GREB1 and AREG, showed higher expression in the
younger cohort, which showed significantly lower ESR1
expression.
A MEDGENE database search (disease terms 'neoplasms',
'breast neoplasms', 'carcinomas', or 'carcinoma, ductal,
breast') indicated that 29 of the 75 differentially expressed
genes had a published first-degree association with cancer; in
contrast, none of the 75 genes had any published association
with aging (disease terms 'aging, premature'). GO analysis
was used to determine whether the 75 genes differentially
expressed between the age cohorts were enriched for specific
Table 1
Gene set enrichment analysis results for the gene list tested
Gene set Comparison
Old over young cohort Progesterone receptor-negative over 
progesterone receptor-positive tumors
ERBB2-negative over ERBB2-positive 
tumors
Enrichment 
score
Nominal P 
value
FWER P 
value
Enrichment 
score
Nominal P 
value
FWER P 
value
Enrichment 
score
Nominal P 
value
FWER P 
value
MAPK 
upregulated
0.44 0.05 0.13 0.28 0.49 0.67 0.28 0.46 0.65
MAPK 
downregulated
-0.36 0.17 0.4 -0.31 0.33 0.57 0.26 0.26 0.68
L u m i n a l  m a r k e r s 0 . 3 10 . 7 20 . 7 9- 0 . 6 3 0 . 1 0 . 1 50 . 4 80 . 3 80 . 5 7
Proliferation 
markers
-0.85 0.006 0.011 0.62 0.32 0.38 -0.83 0.01 0.02
Gene sets showing significant enrichment after adjustment for multiple gene set testing (family-wise error rate (FWER) P < 0.05) are presented in 
bold.Breast Cancer Research    Vol 9 No 5    Yau et al.
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biological processes. Several functional categories were
significantly over-represented (Expression Analysis System-
atic Explorer score < 0.05) in this gene set [43], including
development, cell cycle, M-phase, morphogenesis and repro-
duction. As noted in Table 2, 17 of the genes were associated
with development and nine genes were associated with the
cell cycle, including five genes specifically associated with the
M-phase.
Defining and validating an age cohort signature in ER-
positive breast cancers
PAM was applied to RNA sample set 2 to derive an age cohort
signature consisting of 128 unique genes (145 probes), one-
half of which were overexpressed in the younger cohort rela-
tive to the older cohort and one-half of which were
overexpressed in the older cohort relative to the younger
cohort (Figure 4a). This signature (Additional file 3) was first
validated against RNA sample set 1 and was then independ-
ently validated against two external breast cancer microarray
datasets that included 102 ER-positive cases from Miller and
colleagues [47] and 47 ER-positive cases from Sotiriou and
colleagues [48] fitting our age selection criteria. The PAM-
derived age signature correctly identified older from younger
ER-positive cases in all three validation sample sets with com-
parable accuracy >80% (Figure 4b), and with high statistical
certainty (P = 8.3 × 10-5 to 4.2 × 10-12). Interestingly, the
majority of errors were misclassifications of cases from the
older cohorts as younger cases. Misclassification bias could
not be associated with either nodal status or outcome differ-
ences in the Miller and colleagues and Sotiriou and colleagues
datasets; in fact, when these external validation datasets were
further restricted to node-negative cases to match the training
set, only a modest increase was observed in predictive accu-
racy at the expense of statistical certainty (90%, P = 1.7 × 10-
4 for Sotiriou and colleagues [48]; 86%, P = 1.6 × 10-7 for
Miller and colleagues [47]).
ESR1  and  AREG  were among the 44 genes in common
between the age signature gene set and the differentially
expressed gene set; and, as shown in Figure 4c, age-signa-
ture-defined subsets from all four sample datasets showed
similar differences in mean expression levels (log2 intensity) for
both ESR1 and AREG. Of note, a PR signature was similarly
derived from RNA sample set 2 (103 probes; Additional file 4),
but showed only 67% accuracy (P = 0.1) in predicting the PR
status of RNA sample set 1.
Discussion
Although there have been numerous studies of clinical factors
addressing the relationship between age at diagnosis and
breast cancer prognosis [12,14,16,53-55], few studies have
comprehensively investigated the age dependency of the
many well-established prognostic breast cancer biomarkers,
and no studies have used a prospective study design [13,18].
Figure 3
Estrogen receptor-positive breast cancer subsets by gene set enrichment analysis Estrogen receptor-positive breast cancer subsets by gene set enrichment analysis. Assessment of estrogen receptor (ER)-positive breast cancer 
subsets by gene set enrichment analysis (GSEA) for specific gene signatures. (a) Unsupervised clustering of the 101 primary ER-positive breast 
cancers shown in Figure 2 based only on expression of the 71-gene proliferation signature shown to be significant by GSEA, revealing two major 
clusters (high expressors and low expressors of proliferation signature) with significant biases in age and ERBB2 status; horizontal colored bars 
identify the age cohort, progesterone receptor (PR) status and ERBB2 status of the samples in each column. (b) Kaplan–Meier plots of recurrence 
events among the 54 ER-positive cases with known clinical follow-up, dichotomized by high (red) or low (green) expression of the 71-gene prolifera-
tion signature, with significance determined by log-rank analysis.Available online http://breast-cancer-research.com/content/9/5/R59
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Table 2
Differentially expressed genes between the young and old cohorts
UniGene symbol Fold changea UniGene name
Genes with higher expression in the young cohort
AREGb 3.12 Amphiregulin (schwannoma-derived growth factor)
PRSS2b 2.71 Protease, serine, 2 (trypsin 2)
GREB1b 2.34 GREB1 protein
PTHLHb,d 2.01 Parathyroid hormone-like hormone
HPGDc 1.98 Hydroxyprostaglandin dehydrogenase 15-(NAD)
SPANXA1///SPANXB1///SPANXA2///
SPANXCc///SPANXB2
1.91 Sperm protein associated with the nucleus, X-linked, family member A1///
SPANX family, member B1///SPANX family, member A2///SPANX family, 
member C///SPANX family, member B2
LAMA3d 1.87 Laminin, alpha 3
ATP6V1B1c 1.82 ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit B, isoform 1 (renal 
tubular acidosis with deafness)
S100A2b,d 1.79 S100 calcium binding protein A2
DIO2c 1.79 Deiodinase, iodothyronine, type II
PRSS1b///PRSS2b///PRSS3///TRY6 1.77 Protease, serine, 1 (trypsin 1)///protease, serine, 2 (trypsin 2)///protease, serine, 
3 (mesotrypsin)///trypsinogen C
FGFR1b,d,e 1.65 Fibroblast growth factor receptor 1
TP73Lb,d 1.60 Tumor protein p73-like
PRSS1b 1.59 Protease, serine, 1 (trypsin 1)
C20orf59 1.57 Chromosome 20 open reading frame 59
DLG7b,f 1.56 Discs, large homolog 7 (Drosophila)
ELOVL2c 1.52 Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2
KIF2Cb,f 1.50 Kinesin family member 2C
STK6b,f 1.49 Serine/threonine kinase 6
USTc 1.47 Uronyl-2-sulfotransferase
CDC14Af 1.42 CDC14 cell division cycle 14 homolog A (S. cerevisiae)
ELL3c 1.42 Elongation factor RNA polymerase II-like 3
RAD54Bc,f 1.41 RAD54 homolog B (S. cerevisiae)
ITGA2b,d,e 1.33 Integrin, alpha 2 (CD49B, α2 subunit of VLA-2 receptor)
Genes with higher expression in the old cohort
HOXB6b,d 2.40 Homeobox B6
TMC5 2.36 Transmembrane channel-like 5
HOXB2c,d 1.99 Homeobox B2
ST6GALNAC5 1.99 ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-acetylgalactosaminide α-
2,6-sialyltransferase 5///ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-
acetylgalactosaminide α-2,6-sialyltransferase 5
KIAA1102 1.82 KIAA1102 protein
PYGLc 1.82 Phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)
TNFSF10b 1.82 Tumor necrosis factor (ligand) superfamily, member 10///tumor necrosis factor 
(ligand) superfamily, member 10
GOLPH2c 1.78 Golgi phosphoprotein 2
DSPG3c 1.75 Dermatan sulfate proteoglycan 3
GLRXc 1.75 Glutaredoxin (thioltransferase)
FLJ20152 1.73 Hypothetical protein FLJ20152
GATMc 1.72 Glycine amidinotransferase (l-arginine:glycine amidinotransferase)
ENTPD5b 1.69 Ectonucleoside triphosphate diphosphohydrolase 5Breast Cancer Research    Vol 9 No 5    Yau et al.
Page 10 of 16
(page number not for citation purposes)
SASH1b,f 1.69 SAM and SH3 domain containing 1
ITPR1b 1.68 Inositol 1,4,5-triphosphate receptor, type 1
ANGc,d,e///RNASE4 1.66 Angiogenin, ribonuclease, RNase A family, 5///ribonuclease, RNase A family, 4
IQGAP2b 1.63 IQ motif containing GTPase activating protein 2
MANSC1 1.62 MANSC domain containing 1
HOXB5c,d,e 1.60 Homeobox B5
FAHb 1.60 Fumarylacetoacetate hydrolase (fumarylacetoacetase)
ARHGDIBc,d 1.60 Rho GDP dissociation inhibitor (GDI) beta
TAPBPLc 1.59 TAP binding protein-like
CLMNc 1.56 Calmin (calponin-like, transmembrane)
ESR1b,d,e,f 1.56 Estrogen receptor 1
EFNA1b 1.56 Ephrin-A1
COBLL1 1.56 COBL-like 1
P8b,d,e 1.55 p8 protein (candidate of metastasis 1)
SC5DL 1.52 Sterol-C5-desaturase (ERG3 δ-5-desaturase homolog, fungal)-like
CLEC5A 1.52 C-type lectin domain family 5, member A
SEPT6f 1.52 Septin 6
RHOBb,d,e,f 1.52 Ras homolog gene family, member B
CYB5 1.51 Cytochrome b-5
PDE4Ab 1.50 Phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog, 
Drosophila)
C21orf25 1.49 Chromosome 21 open reading frame 25
CCL3c///CCL3L1///CCL3L3 1.49 Chemokine (C–C motif) ligand 3///chemokine (C–C motif) ligand 3-like 1///
chemokine (C–C motif) ligand 3-like 3
CCDC28A 1.46 Coiled-coil domain containing 28A
CALM3 1.46 Calmodulin 3 (phosphorylase kinase, delta)
PPFIBP2c 1.46 PTPRF interacting protein, binding protein 2 (liprin β2)
DBIc 1.46 Diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding 
protein)
SLC25A12c 1.45 Solute carrier family 25 (mitochondrial carrier, Aralar), member 12
CPMb,d,e 1.44 Carboxypeptidase M
MARCH8 1.43 Membrane-associated ring finger (C3HC4) 8
FLJ20298 1.41 FLJ20298 protein
SLC12A8c 1.40 Solute carrier family 12 (potassium/chloride transporters), member 8
FUCA1b 1.39 Fucosidase, alpha-L-1, tissue
LOC57146 1.38 Promethin
RANBP2c 1.36 RAN binding protein 2
HOXB7b,d 1.36 Homeobox B7
PANX1c 1.33 Pannexin 1
TGOLN2b 1.31 trans-Golgi network protein 2
VWA1c 1.29 von Willebrand factor A domain containing 1
aYoung/old for genes with higher expression in the young cohort; old/young for genes with higher expression in the old cohort. bGenes showing 
first-degree association with cancer and cgenes showing second-degree association with cancer (associations as determined through MEDGENE 
database searches with terms Carcinoma, Ductal Breast Carcinoma, Neoplasms and Breast Neoplasms). dGenes involved in 'development', 
egenes involved in morphogenesis and fgenes involved in the cell cycle, as functionally annotated by the DAVID database and contributed to the 
enrichment probability calculations – these three major gene ontology biological processes were found to be enriched among the 75 differentially 
expressed genes. Enrichment was defined as Expression Analysis Systematic Explorer score < 0.05.
Table 2 (Continued)
Differentially expressed genes between the young and old cohortsAvailable online http://breast-cancer-research.com/content/9/5/R59
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Concerned about the established inverse relationship
between the ER status and poor-risk biomarker surrogates of
breast cancer proliferation and genomic instability [13,18], the
present study aimed to identify genomic and transcriptome
changes associated with aging using DNA and RNA prospec-
tively collected from stage-matched and histology-matched
ER-positive breast cancers from younger women (age ≤ 45
years) and older women (age ≥ 70 years), analyzed by array
CGH and high-throughput expression microarrays.
Similar bioinformatics-based approaches have been used to
characterize aging effects in human fibroblasts [5,6], lym-
phocytes [5] and myoblasts [56]; however, comparable efforts
to investigate aging influences on human cancer biology have
not been reported. Moreover, while ER-positive breast can-
cers have been well studied as a subgroup within unselected
breast cancer phenotypes using array CGH [28,57] or expres-
sion profiling [38,39,49-51], the present study represents the
largest study reported to date using these powerful tech-
niques to subset ER-positive breast cancers, while employing
a statistical design powered to detect age-specific
differences.
Array CGH analysis of 71 DNA samples confirmed that our
ER-positive breast cancers were composed of two basic gen-
otypes [28]: a simple subtype characterized by few genomic
copy number changes other than gain of 1q and loss of 16q,
and a mixed amplifier subtype characterized by recurrent
amplifications but otherwise low levels of genomic gains and
losses. A third genomic subtype of breast cancer, referred to
as complex, known to be almost exclusively composed of ER-
negative breast cancers [28], was not observed in either of the
two age cohorts studied. Neither the simple nor the mixed
amplifier genomic subtypes of ER-positive breast cancer
showed any particular age bias. Direct comparison of the two
age cohorts for multiple array CGH parameters also revealed
Figure 4
Prediction analysis of microarrays-derived age signature validated against independent estrogen receptor-positive breast cancer datasets Prediction analysis of microarrays-derived age signature validated against independent estrogen receptor-positive breast cancer datasets. (b) Uni-
versity of California San Francisco (UCSF) RNA sample set 2 (n = 66, younger women and older women) was used to train prediction analysis of 
microarrays (PAM) and to derive a 145-probe (128-gene) age cohort classifying signature, arranged in ascending order of the PAM score for cases 
in the older cohort. (b) Actual and signature-predicted age cohort designations for the validating UCSF RNA sample set 1 (n = 35) and two external 
validating datasets restricted to estrogen receptor-positive cases with identical age cohort characteristics: Sotiriou and colleagues [48] and Miller 
and colleagues [47]. Prediction accuracies are indicated, with Fisher's exact test P values presented for significance. (c) Age-signature-defined sub-
sets from all four sample datasets show similar differences in log2 expression levels (mean ± standard deviation) of AREG and ESR1.Breast Cancer Research    Vol 9 No 5    Yau et al.
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no significant differences in the fraction of genome altered, in
whole chromosome changes or in total or site-specific
amplicon frequencies. Although nonsignificant trends sug-
gested slightly fewer oncogene amplifications within the older
cohort, overall amplification frequencies for the most common
oncogenes were as expected for ER-positive breast cancers
[51,58]: MYC (27%), CCND1 (23%), ZNF217 (17%), AIB1
(16%),  MDM2  (8%),  ESR1  (7%),  ERBB2  (7%), and
TOPO2A (7%). At the level of genomic resolution (~1 MB)
achievable by BAC-based array CGH, there appeared to be
few if any genetic differences between ER-positive breast can-
cers arising in women whose ages differ by more than 25
years. Future studies employing higher density genomic arrays
are warranted to confirm this conclusion.
Microarray profiling of 101 RNA samples showed an average
65-fold range in ESR1 transcript levels across the entire col-
lection of ER-positive breast cancers, with the older cohort
showing significantly higher ESR1 levels as compared with
the younger cohort, consistent with earlier biomarker studies
[13]. There was the expected close correlation between the
ESR1 transcript levels and commonly observed ESR1 coex-
pressed genes (for example, GATA3) as well as other genes
(for example, KRT8,  KRT18) that characteristically define
luminal-type breast cancer, although this tumor collection also
contained several ERBB2-positive cases (10/101) that are
not characteristically found in microarray-defined clusters of
luminal-type breast cancer [38,39,49-51]. Hierarchical clus-
tering of the ~5.1 K variably expressed genes also identified
six transcriptome subtypes of ER-positive breast cancer with
significant age biases (P < 0.05) but not associated with dif-
fering PR status. Based on relapse-free survival analyses of
the 54 cases with known clinical outcome (30 younger
women, 24 older women), there was a trend supporting a less
favorable prognosis for the younger age cases (P = 0.09) and
PR-negative cases (P = 0.08). The six age-biased transcrip-
tome clusters, however, showed significantly different relapse-
free survival outcomes (P = 0.025, log-rank analysis), suggest-
ing that these transcriptome subtypes represent clinically rele-
vant phenotypes of ER-positive breast cancer. Previous
expression array studies analyzing fewer ER-positive cases
have identified no more than two or three subsets of luminal-
type breast cancer [38,39,49-51].
Reported gene signatures representing luminal, proliferation
and MAPK markers were tested for their enrichment in one or
the other of the age-stratified cohorts, and only the prolifera-
tion gene signature showed any significant age bias when mul-
tiple testing was accounted for, being more highly expressed
in the younger cohort. This finding is consistent with earlier
studies showing higher tumor grade and proliferation markers
(for example, mitotic index and Ki-67 positivity) in younger age
breast cancer patients [13]. While none of the >1,000 curated
gene sets in the Molecular Signature Database that were sim-
ilarly evaluated demonstrated any significant age biases when
multiple testing was account for, a trend was observed for
enrichment of cell cycle genes in the younger cohort cases.
Nine genes common to both the GO biological process cell
cycle set and the proliferation signature set (BUB1, CCNB1,
CCNE2,  CDC25A,  CDC7,  MAD2L1,  MCM4,  ORC6L,
PTTG1) were also present in our significant probe set. Among
these, four genes (BUB1, CCNE2, MAD2L1, ORC6L) have
been previously associated with poor-prognosis ER-positive
breast cancers in a well-established 70-gene prognostic
signature [58]; these genes are therefore probably important
contributors to the more aggressive tumor characteristics of
ER-positive breast cancers arising in younger patients.
Using only the proliferation gene signature to perform unsu-
pervised hierarchical clustering of the 101 cases generated
two comparably sized ER-positive subsets, one with higher
expression and another with lower expression of the prolifera-
tion genes; the higher expressing subset contained most of
the younger age cases (34/52) and all but one of the ERBB2-
positive cases. When this proliferation signature was also
used to dichotomize the 54 cases with known clinical out-
come, the higher expressing cases showed significantly worse
disease-free survival as compared with the lower expressing
cases, consistent with reports on the association of a similar
proliferation signature with poor outcome in patients with ER-
positive breast cancer [59]. Interestingly, despite a presumed
mechanistic link between activation of growth factor recep-
tors, MAPK signaling and cell proliferation, there was minimal
overlap between genes in the reported MAPK and proliferation
signatures, and no significant association was observed
between the MAPK signature, age and ERBB2 positivity.
Despite the observed positive association between the ESR1
expression level and older age, no age association was seen
for the luminal gene signature that included ESR1, ESR1-
associated genes and estrogen-inducible genes. This finding
is consistent with our previous report showing increased
breast cancer ER protein with aging without comparably
increased levels of such estrogen-inducible markers as PR,
pS2, Bcl2 and cathepsin D [13], and suggesting reduced
estrogen signaling in breast tumors of older patients. In keep-
ing with these protein biomarker observations, differential
gene expression analysis in the present study did not identify
any known estrogen-inducible genes such as TFF1,  PGR,
IRS1, IGFBP4, PCNA, MYC, CCNA2 or DLEU2 as being
more highly expressed in the older cohort despite higher
expression of ESR1 in this cohort. In contrast, two estrogen-
inducible growth-regulating genes, GREB1  and  AREG,
showed significantly higher expression levels in the younger
cohort, in keeping with a recent study demonstrating a nega-
tive correlation between these estrogen-inducible genes and
age [20]. As GREB1 and AREG are known to induce cell pro-
liferation upon estrogen activation [60,61], their increased
expression in the younger cohort offers some mechanisticAvailable online http://breast-cancer-research.com/content/9/5/R59
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basis for increased proliferative activity and gene expression in
the younger cohort.
Of the 75 unique genes differentially expressed between
younger and older cohorts, 24 genes showed increased
expression in younger cases relative to older cases (including
GREB1  and  AREG) while 51 genes showed increased
expression in older cases relative to younger cases (including
ESR1). Comparison with a well-studied estrogen-inducible
gene signature set [20] revealed that ~25% (19/75) of these
differentially expressed genes overlapped with known early or
late estrogen-responsive genes, and thus potentially reflected
hormonal changes associated with menopause rather than
aging effects. While two-thirds (13/19) of these potential
estrogen-responsive genes showed appropriate directional
changes according to cohort menopausal status, supporting
this possibility, at least 75% of the differentially expressed
genes would appear to be independent of menopausal differ-
ences in circulating estrogen levels and, therefore, potentially
informative of age-related differences in ER-positive breast
cancer biology. A comprehensive database search confirmed
that at least 40% of these differentially expressed genes have
reported direct links with malignancy; and while none have
reported links with premature aging, one of the differentially
expressed genes (KIF2C) has been previously implicated in
aging studies of lymphocytes and fibroblasts [5], while six
other genes (COBLL1, HPGD, HOXB2, PDE4A, SLC25A12,
TP73L) were recently reported as differentially expressed with
age in human skeletal muscle [62].
A search for annotated enrichment of the differentially
expressed genes for specific biological processes (GO Bio-
logical Processes, Expression Analysis Systematic Explorer
score < 0.05) indicated that 'development' and 'cell cycle/M-
phase' were the most overrepresented functional gene cate-
gories. In keeping with the GSEA observation indicating a
trend for enrichment of cell-cycle-associated genes in the
younger cohort cases, differentially expressed cell cycle/M-
phase genes (including positive regulators such as STK6,
FGFR1 and DLG7) represented 20% (5/25) of all genes over-
expressed in the younger cohort but only 8% (4/51) of those
overexpressed in the older cohort. In contrast, the older cohort
cases showed differentially increased expression of negative
cell cycle regulators (such as SASHI and RHOB) and four
developmentally essential homeobox genes (HOXB2,
HOXB5, HOXB6, HOXB7), the latter finding also in keeping
with the GSEA observed trend showing enrichment in the
older cohort of HOX-regulated (NUP90-HOXA9 repressed)
genes. Two of the overexpressed HOXB genes (HOXB6,
HOXB7) have been specifically linked to mammary gland
development and are known to be expressed in ER-positive
breast cancer cells [63]. HOXB7, in particular, known to be
dependent on stromal (extracellular matrix) signaling, is tran-
scriptionally upregulated in breast cancers metastatic to bone
(relative to primary tumors), and is thought to play a role in
promoting angiogenesis, growth factor-independent prolifera-
tion and DNA double-strand break repair, conferring breast
cancer resistance to the genome destabilizing effects of DNA
damage [64].
PAM was used to derive an age signature that consisted of
128 unique genes, including 44 of the 75 differentially
expressed genes determined by our conditional permutation
approach. The age signature was independently validated
against two other age-matched ER-positive breast cancer
microarray datasets and proved to have >80% accuracy in
distinguishing younger from older ER-positive breast cancer
cases. ESR1 and AREG were among the genes in common
between the age signature and the differentially expressed
gene sets; it is therefore not surprising that the age-signature-
defined subsets from the two independent databases showed
similar differences in the mean expression levels of these two
genes as found in our age-defined cohorts. Only 28% of the
age signature genes overlap with known early or late estrogen-
responsive genes, suggesting that this age signature largely
reflects age-related differences in the phenotype of ER-posi-
tive breast cancer rather than differences in circulating estro-
gen levels associated with menopausal status.
The fact that a PAM-derived PR signature did not perform well
upon validation implies substantial heterogeneity between ER-
positive breast cancers with the same PR status, and possibly
indicates that confounding age-related gene expression
changes are of greater biological importance than PR-related
gene expression differences. Misclassification errors using the
age signature were more prevalent among the older cohort
cases, also suggesting greater variation in expression of the
age signature genes with aging. Of further interest, the 128
age signature gene set was unable to accurately subset ER-
negative cases identified from the two independent breast
cancer datasets [47,48], consistent with expression-array-
based conclusions that the biology of ER-positive and ER-neg-
ative breast cancers are fundamentally distinct, and
supporting the likelihood that the PAM-derived age signature
incorporates biological profiles specific to ER-positive breast
cancers but not ER-negative breast cancers.
Conclusion
This prospectively designed study addresses a pressing need
to evaluate molecular and cellular hypotheses proposed to
explain age-related differences in breast cancer incidence and
clinical behavior. It is hard to reconcile the evidence gathered
in this study of ER-positive breast cancers with the more gen-
eral cancer-aging postulate that the breast-cancer-prone phe-
notype of an older woman results from genomic instability and
age-accumulated mutational loads secondary to telomeric
dysfunction and/or progressive DNA damage [9]. More con-
sistent with the present evidence is the likelihood that ER-pos-
itive breast cancers arising in older women relative to younger
women do so by a fundamentally different tumorigenic proc-Breast Cancer Research    Vol 9 No 5    Yau et al.
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ess, manifested more by epigenetic transcriptome differences
such as those regulated by HOX genes, and less by genomic
differences that were not detected using state-of-the-art BAC-
based CGH analyses. More pronounced expression of cell
cycle and proliferation-associated genes emerged as a strong
defining feature of ER-positive breast cancers arising in
younger women, perhaps even driving their earlier clinical
appearance; this observation is certainly consistent with the
more aggressive clinical nature of early-age-onset breast
cancer.
Age cohort study designs of this type are needed to not only
confirm the specific transcriptome differences noted here, but
also to look for common age-associated differences in gene
classes and functional pathways that may enable us to gener-
alize about the age-related biological differences driving ER-
negative breast tumorigenesis as well as the many other age-
associated epithelial malignancies other than breast cancer.
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